Last reviewed · How we verify
NCT07000331
Effectiveness of Exercise and Physical Activity in Individuals.
NA trial testing Thoracic expansion exercises in COVID-19 in 41 participants. Completed in 30 December 2024.
30 August 2024
Quick facts
| Lead sponsor | Gulsah Bargi |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | supportive care |
| Enrollment | 41 |
| Start date | 16 February 2023 |
| Primary completion | 30 August 2024 |
| Estimated completion | 30 December 2024 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Thoracic expansion exercises
- Physical activity counseling
Conditions studied
- COVID-19 — all drugs for COVID-19 →
Sponsor
Gulsah Bargi
Who can join
18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The effects of breathing exercises and physical activity counseling applied for 4 weeks on the number of daily steps, dyspnea, pain, fatigue, mood and quality of life in individuals who have just had COVID-19 are not yet known. For this reason, it was aimed to investigate in this study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07000331
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Thoracic expansion exercises
Trials testing the same drug.
- NCT06092528 — Investigation of the Effects of Pulmonary Rehabilitation in Children With Primary Immunodeficiency · NA · recruiting
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Gulsah Bargi trials
Trials by the same sponsor.
- NCT06042374 — Core Stabilization Training in Elite Athletes · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07000331 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Gulsah Bargi
- Last refreshed: 4 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07000331.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing